Skip to main content
. 2010 May 24;9:118. doi: 10.1186/1476-4598-9-118

Figure 3.

Figure 3

Expression of Siglec-9 on NK cells, B cells and monocytes. PBMC from healthy donors (HD) and PBMC and PFMC from patients (PT) were labeled with fluorophore conjugated anti-CD3, -CD19, -CD16, -CD33, -CD45, -CD56, and -Siglec-9 antibodies. Cells were analyzed by flow cytometry. Live and single events were gated and expression of Siglec-9 on CD16pos/CD56dim (NK) cells, CD19pos B cells, and CD33pos monocytes was determined. Data shown for HD #29 and PT#36 is representative of that obtained for four healthy donors and five ovarian cancer patients, respectively.